Diagnosis and Treatment of Diffuse Large B-Cell Lymphoma

Introduction to DLBCL Treatment

• The European Society for Medical Oncology recommends R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy given every 21 days for 6-8 cycles, with careful attention to HIV status and CNS prophylaxis given the high-risk features 1, 2, 3

Diagnosis Confirmation

• The biopsy findings of diffuse large B cells with irregular nuclei disrupting normal lymph node architecture is diagnostic of DLBCL, according to the European Society for Medical Oncology 1, 4
• Immunohistochemistry must confirm CD20 positivity (along with CD45 and CD3 as minimum panel) to ensure eligibility for rituximab-based therapy, as recommended by the European Society for Medical Oncology 1, 3
• The presence of HIV is particularly relevant as HIV-associated lymphomas can be more aggressive, as noted by the European Society for Medical Oncology 5, 2

Immediate Staging Workup Required

• A CT scan of chest, abdomen, and pelvis is required before initiating treatment, as recommended by the European Society for Medical Oncology 1, 4, 3
• A PET/CT scan is strongly recommended to better delineate disease extent and for future response assessment, according to the European Society for Medical Oncology 1, 3
• A bone marrow aspirate and biopsy are necessary, as recommended by the European Society for Medical Oncology 1, 2, 3

Critical: CNS Prophylaxis Consideration

• The patient requires CNS prophylaxis with intrathecal chemotherapy (cytarabine and/or methotrexate), as recommended by the European Society for Medical Oncology 5, 2
• High-risk features present include multiple extranodal sites and HIV-positive status, which increase CNS risk, as noted by the European Society for Medical Oncology 5, 2

Standard Treatment Protocol

• The standard treatment is R-CHOP, which includes rituximab 375 mg/m² IV on Day 1 of each cycle, as recommended by the European Society for Medical Oncology 3
• Cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) are given every 21 days, according to the European Society for Medical Oncology 1, 2, 3
• A total of 6-8 cycles are given depending on response and tolerability, as recommended by the European Society for Medical Oncology 1, 2, 3

Critical Management Considerations

• Tumor lysis syndrome prophylaxis is mandatory given the high tumor burden, as recommended by the European Society for Medical Oncology 2, 4, 3
• Aggressive hydration, allopurinol or rasburicase, and electrolyte monitoring are necessary, according to the European Society for Medical Oncology 2, 3
• HIV management during chemotherapy includes continuing antiretroviral therapy throughout treatment, as recommended by the European Society for Medical Oncology 5, 2
• Prophylactic antibiotics (PCP prophylaxis with trimethoprim-sulfamethoxazole) are necessary, according to the European Society for Medical Oncology 5
• Hematopoietic growth factors (G-CSF) should be used prophylactically to prevent febrile neutropenia, as recommended by the European Society for Medical Oncology 2, 3

Response Assessment

• After 3-4 cycles, repeat imaging (CT or PET/CT) to assess response, as recommended by the European Society for Medical Oncology 3
• PET/CT is highly recommended for accurate response evaluation, according to the European Society for Medical Oncology 1, 3
• Complete the full 6-8 cycles if responding, as recommended by the European Society for Medical Oncology 1, 2, 3

Prognosis and Risk Stratification

• The patient has several adverse prognostic factors, including HIV-positive status, multiple extranodal sites, and B symptoms, as noted by the European Society for Medical Oncology 1, 2, 3
• The IPI score will likely be intermediate-high or high risk (≥2), which typically indicates a more aggressive approach may be needed, though R-CHOP every 21 days remains the standard initial therapy, according to the European Society for Medical Oncology 1, 2, 3

Evidence‑Based Facts on Diffuse Large B‑Cell Lymphoma (DLBCL)

Epidemiology & Risk Factors

• DLBCL is the most common aggressive non‑Hodgkin lymphoma, representing 30–58 % of all NHL cases and showing a crude European incidence of 3.8 cases per 100 000 population per year. 6
• Documented risk factors include family history of lymphoma, autoimmune disease, HIV infection, HCV seropositivity, high body‑mass index in early adulthood, and occupational exposures. 6

Diagnostic Standards

• Surgical excisional biopsy (unfixed tissue) is the gold‑standard diagnostic approach because it preserves nodal architecture and provides sufficient material for phenotypic and molecular analyses. 6
• Fine‑needle aspiration alone is not acceptable for definitive diagnosis. 6
• Core‑needle or endoscopic biopsies are reserved only for patients in whom surgery is impractical or poses excessive risk. 6

Essential Immunohistochemistry Panel

• The minimum IHC panel required to confirm B‑cell lineage and exclude mimics must contain CD20, CD79a, BCL6, CD10, MYC, BCL2, Ki‑67, IRF4, Cyclin D1, CD5, and CD23. 6
• EBER‑1 staining is used to identify the EBV‑positive DLBCL subtype in elderly patients. 6
• PCR‑based B‑cell monoclonality testing should be considered when diagnostic confidence is reduced. 6

Cell‑of‑Origin Classification

• Gene‑expression profiling separates DLBCL into germinal‑center B‑cell (GCB) and activated B‑cell (ABC) subtypes. 6
• The GCB phenotype is associated with significantly better clinical outcomes than the ABC phenotype. 6
• Although a major prognostic factor, cell‑of‑origin classification does not currently modify standard first‑line therapy. 6

Staging & Baseline Laboratory Workup

• Baseline investigations required for staging include LDH, complete blood count, comprehensive metabolic panel, HIV testing, and HCV serology. 6

Prognosis & Survival Trends

• Rituximab‑based therapy has led to significant improvements in survival across all European regions. 6

Differential Diagnosis

• Blastic mantle‑cell lymphoma should be considered among the key differential diagnoses for DLBCL. 6